Literature DB >> 26228080

Prospective study on the components of metabolic syndrome and the incidence of Parkinson's disease.

Katri Sääksjärvi1, Paul Knekt2, Satu Männistö3, Jukka Lyytinen4, Markku Heliövaara5.   

Abstract

INTRODUCTION: Inconsistent results regarding the association between the components of metabolic syndrome and Parkinson's disease (PD) have been reported. We investigated whether the metabolic syndrome or its components, or serum total cholesterol, predict PD incidence in a prospective cohort study design.
METHODS: The study was based on the Mini-Finland Health Survey including 6641 individuals aged 30-79 and free from PD at baseline (1978-1980). During 30 years of follow-up, 89 incident PD cases occurred.
RESULTS: After adjustment for sociodemographic and lifestyle factors, the relative risk (RR) of PD was 0.50 (95% confidence interval (CI): 0.30, 0.83) for individuals with the metabolic syndrome compared to those without. This association was especially due to elevated serum triglyceride concentration (≥1.7 vs.<1.7 mmol/L, RR = 0.52, 95%CI: 0.30-0.89, P for trend 0.02) and elevated plasma fasting glucose concentration (≥5.6 vs.<5.6 mmol/L, RR = 0.56 0.32, 0.98, P for trend 0.05). Elevated serum triglyceride and plasma fasting glucose concentration predicted lower PD risk even after excluding the first 10 years of follow-up. After this exclusion and further adjustment for other components of the metabolic syndrome, a suggestively increased PD risk was observed in overweight individuals (≥25 kg/m(2) vs.<25 kg/m(2), RR = 1.75, 95%CI: 1.00, 3.07, P for trend 0.22). Blood pressure, serum HDL cholesterol, or serum total cholesterol carried no prediction of PD risk.
CONCLUSION: Elevated serum triglyceride and plasma fasting glucose concentrations predict low PD incidence whereas high BMI seems to be suggestively related to an increased PD risk.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biological markers; Cohort studies; Metabolic syndrome; Parkinson's disease; Risk factors

Mesh:

Substances:

Year:  2015        PMID: 26228080     DOI: 10.1016/j.parkreldis.2015.07.017

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  19 in total

1.  Understanding the links between cardiovascular disease and Parkinson's disease.

Authors:  Judy Potashkin; Xuemei Huang; Claudia Becker; Honglei Chen; Thomas Foltynie; Connie Marras
Journal:  Mov Disord       Date:  2019-09-04       Impact factor: 10.338

2.  Glucose levels during life and neuropathologic findings at autopsy among people never treated for diabetes.

Authors:  Paul K Crane; Rod L Walker; Joshua Sonnen; Laura E Gibbons; Rebecca Melrose; Jason Hassenstab; C Dirk Keene; Nadia Postupna; Thomas J Montine; Eric B Larson
Journal:  Neurobiol Aging       Date:  2016-08-01       Impact factor: 4.673

Review 3.  Management of Hypertension and Blood Pressure Dysregulation in Patients with Parkinson's Disease-a Systematic Review.

Authors:  Vasiliki Katsi; Ilias Papakonstantinou; Eirini Solomou; Alexios S Antonopoulos; Charalambos Vlachopoulos; Konstantinos Tsioufis
Journal:  Curr Hypertens Rep       Date:  2021-05-07       Impact factor: 5.369

4.  Impact of disease duration and cardiovascular dysautonomia on hypertension in Parkinson's disease.

Authors:  Davide L Vetrano; Maria S Pisciotta; Vincenzo Brandi; Maria R Lo Monaco; Alice Laudisio; Graziano Onder; Domenico Fusco; Paolo D L'Angiocola; Anna R Bentivoglio; Roberto Bernabei; Giuseppe Zuccalà
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-11-02       Impact factor: 3.738

Review 5.  Milk: an epigenetic amplifier of FTO-mediated transcription? Implications for Western diseases.

Authors:  Bodo C Melnik
Journal:  J Transl Med       Date:  2015-12-21       Impact factor: 5.531

6.  Integrated molecular landscape of Parkinson's disease.

Authors:  J E Visser; G Poelmans; C J H M Klemann; G J M Martens; M Sharma; M B Martens; O Isacson; T Gasser
Journal:  NPJ Parkinsons Dis       Date:  2017-04-10

7.  Metabolic syndrome and risk of Parkinson disease: A nationwide cohort study.

Authors:  Ga Eun Nam; Seon Mee Kim; Kyungdo Han; Nan Hee Kim; Hye Soo Chung; Jin Wook Kim; Byoungduck Han; Sung Jung Cho; Ji Hee Yu; Yong Gyu Park; Kyung Mook Choi
Journal:  PLoS Med       Date:  2018-08-21       Impact factor: 11.069

8.  Hypertension and Diagnosis of Parkinson's Disease: A Meta-Analysis of Cohort Studies.

Authors:  Liyan Hou; Qiujuan Li; Liping Jiang; Hongyan Qiu; Chengyan Geng; Jau-Shyong Hong; Huihua Li; Qingshan Wang
Journal:  Front Neurol       Date:  2018-03-19       Impact factor: 4.003

9.  Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson's disease.

Authors:  Avner Thaler; Shani Shenhar-Tsarfaty; Yanay Shaked; Tanya Gurevich; Nurit Omer; Anat Bar-Shira; Mali Gana-Weisz; Orly Goldstein; Meir Kestenbaum; Jesse M Cedarbaum; Avi Orr-Urtreger; Nir Giladi; Anat Mirelman
Journal:  Sci Rep       Date:  2020-06-09       Impact factor: 4.379

10.  Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores.

Authors:  Maureen Leehey; Sheng Luo; Saloni Sharma; Anne-Marie A Wills; Jacquelyn L Bainbridge; Pei Shieen Wong; David K Simon; Jay Schneider; Yunxi Zhang; Adriana Pérez; Rohit Dhall; Chadwick W Christine; Carlos Singer; Franca Cambi; James T Boyd
Journal:  Neurology       Date:  2017-09-29       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.